Ghent University Academic Bibliography

Advanced

A four-gene promoter methylation marker panel consisting of GREM1, NEURL, LAD1, and NEFH predicts survival of clear cell renal cell cancer patients

Iris JH van Vlodrop, Sophie C Joosten, Tim De Meyer UGent, Kim M Smits, Leander Van Neste UGent, Veerle Melotte, Marcella MLL Baldewijns, Leo J Schouten, Piet A van den Brandt, Jana Jeschke, et al. (2017) CLINICAL CANCER RESEARCH. 23(8). p.2006-2018
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
CPG ISLAND HYPERMETHYLATION, HIPPEL-LINDAU GENE, CARCINOMA, MUTATIONS, EXPRESSION, PROGNOSIS, INACTIVATION, NETHERLANDS, EVOLUTION, RECEPTOR
journal title
CLINICAL CANCER RESEARCH
Clin. Cancer Res.
volume
23
issue
8
pages
2006 - 2018
Web of Science id
000399188300017
ISSN
1078-0432
1557-3265
DOI
10.1158/1078-0432.ccr-16-1236
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
8509339
handle
http://hdl.handle.net/1854/LU-8509339
date created
2017-02-13 21:03:51
date last changed
2018-01-29 08:33:38
@article{8509339,
  author       = {van Vlodrop, Iris JH and Joosten, Sophie C and De Meyer, Tim and Smits, Kim M and Van Neste, Leander and Melotte, Veerle and Baldewijns, Marcella MLL and Schouten, Leo J and van den Brandt, Piet A and Jeschke, Jana and Yi, Joo Mi and Schuebel, Kornel E and Ahuja, Nita and Herman, James G and Aarts, Maureen J and Bosman, Fred T and Van Criekinge, Wim and van Engeland, Manon},
  issn         = {1078-0432},
  journal      = {CLINICAL CANCER RESEARCH},
  keyword      = {CPG ISLAND HYPERMETHYLATION,HIPPEL-LINDAU GENE,CARCINOMA,MUTATIONS,EXPRESSION,PROGNOSIS,INACTIVATION,NETHERLANDS,EVOLUTION,RECEPTOR},
  language     = {eng},
  number       = {8},
  pages        = {2006--2018},
  title        = {A four-gene promoter methylation marker panel consisting of GREM1, NEURL, LAD1, and NEFH predicts survival of clear cell renal cell cancer patients},
  url          = {http://dx.doi.org/10.1158/1078-0432.ccr-16-1236},
  volume       = {23},
  year         = {2017},
}

Chicago
van Vlodrop, Iris JH, Sophie C Joosten, Tim De Meyer, Kim M Smits, Leander Van Neste, Veerle Melotte, Marcella MLL Baldewijns, et al. 2017. “A Four-gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients.” Clinical Cancer Research 23 (8): 2006–2018.
APA
van Vlodrop, I. J., Joosten, S. C., De Meyer, T., Smits, K. M., Van Neste, L., Melotte, V., Baldewijns, M. M., et al. (2017). A four-gene promoter methylation marker panel consisting of GREM1, NEURL, LAD1, and NEFH predicts survival of clear cell renal cell cancer patients. CLINICAL CANCER RESEARCH, 23(8), 2006–2018.
Vancouver
1.
van Vlodrop IJ, Joosten SC, De Meyer T, Smits KM, Van Neste L, Melotte V, et al. A four-gene promoter methylation marker panel consisting of GREM1, NEURL, LAD1, and NEFH predicts survival of clear cell renal cell cancer patients. CLINICAL CANCER RESEARCH. 2017;23(8):2006–18.
MLA
van Vlodrop, Iris JH, Sophie C Joosten, Tim De Meyer, et al. “A Four-gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients.” CLINICAL CANCER RESEARCH 23.8 (2017): 2006–2018. Print.